Research and Markets: Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Between 2010 and 2018, the Global ADH

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/38aeb5/attention_deficit) has announced the addition of GlobalData's new report "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

GlobalData estimates that the global Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010 three drugs, namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), were approved in the US. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, this has resulted in high acceptance of Vyvanse in the US despite its high treatment cost in comparison with the existing therapies. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, which resulted in a decline in the US market, in turn triggering a decline in the global ADHD market in 2009.

The growth rate is similar across the US and European countries, but is significantly higher in Japan (18.4%). This disparity across geographical markets exists because of the variation in the approval dates for some of the drugs in the US, Europe and Japan. In the US, therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved, whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, and its acceptance across Europe is predicted to represent a growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have a similar mode of action to that of existing drugs, and are therefore unlikely to impact the market significantly.

Companies Mentioned:

  • Curemark, LLC.
  • Johnson & Johnson
  • NextWave Pharmaceuticals
  • Novartis AG
  • Shire Plc.

For more information visit http://www.researchandmarkets.com/research/38aeb5/attention_deficit



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Europe  Ireland

INDUSTRY KEYWORDS:   Health  Mental Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.